Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Robotic Surgical Procedures | 4 | 2025 | 160 | 2.830 |
Why?
|
| Pneumonectomy | 5 | 2025 | 116 | 2.730 |
Why?
|
| Lung Neoplasms | 13 | 2025 | 695 | 2.630 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2025 | 174 | 1.690 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2014 | 358 | 1.470 |
Why?
|
| Esophagectomy | 3 | 2024 | 48 | 1.260 |
Why?
|
| Esophageal Neoplasms | 2 | 2024 | 86 | 1.170 |
Why?
|
| Thoracic Surgical Procedures | 2 | 2025 | 42 | 0.980 |
Why?
|
| Conversion to Open Surgery | 1 | 2025 | 14 | 0.920 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2025 | 61 | 0.890 |
Why?
|
| Thoracic Surgery | 2 | 2025 | 76 | 0.890 |
Why?
|
| Resuscitation | 1 | 2025 | 74 | 0.880 |
Why?
|
| Databases, Factual | 3 | 2025 | 856 | 0.860 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2025 | 126 | 0.850 |
Why?
|
| Anastomotic Leak | 1 | 2024 | 35 | 0.830 |
Why?
|
| Frailty | 2 | 2022 | 125 | 0.800 |
Why?
|
| Societies, Medical | 1 | 2025 | 381 | 0.770 |
Why?
|
| General Surgery | 1 | 2025 | 214 | 0.770 |
Why?
|
| Education, Medical, Graduate | 1 | 2025 | 350 | 0.750 |
Why?
|
| Retrospective Studies | 16 | 2025 | 6732 | 0.730 |
Why?
|
| Neoplasm Staging | 8 | 2021 | 529 | 0.690 |
Why?
|
| Robotics | 1 | 2022 | 87 | 0.670 |
Why?
|
| Analgesics, Opioid | 1 | 2025 | 531 | 0.640 |
Why?
|
| Quality Improvement | 2 | 2024 | 455 | 0.630 |
Why?
|
| Opioid-Related Disorders | 1 | 2025 | 513 | 0.550 |
Why?
|
| Internship and Residency | 1 | 2025 | 808 | 0.540 |
Why?
|
| Aged | 15 | 2025 | 14657 | 0.520 |
Why?
|
| Neoplasms, Second Primary | 2 | 2014 | 50 | 0.480 |
Why?
|
| Adenocarcinoma | 3 | 2014 | 356 | 0.440 |
Why?
|
| Male | 18 | 2025 | 30305 | 0.430 |
Why?
|
| Carcinoid Tumor | 1 | 2013 | 13 | 0.400 |
Why?
|
| Emergencies | 2 | 2025 | 121 | 0.400 |
Why?
|
| Middle Aged | 11 | 2025 | 17906 | 0.390 |
Why?
|
| Humans | 23 | 2025 | 64252 | 0.390 |
Why?
|
| Risk Assessment | 5 | 2024 | 2047 | 0.390 |
Why?
|
| Female | 16 | 2025 | 33360 | 0.390 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2013 | 259 | 0.370 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 1669 | 0.370 |
Why?
|
| Postoperative Complications | 3 | 2025 | 1294 | 0.310 |
Why?
|
| Clinical Competence | 2 | 2025 | 728 | 0.290 |
Why?
|
| United States | 4 | 2025 | 7923 | 0.290 |
Why?
|
| Risk Factors | 5 | 2024 | 5339 | 0.270 |
Why?
|
| New York | 3 | 2014 | 143 | 0.230 |
Why?
|
| Adult | 8 | 2025 | 17121 | 0.220 |
Why?
|
| Delphi Technique | 1 | 2025 | 102 | 0.220 |
Why?
|
| Survival Rate | 4 | 2014 | 859 | 0.220 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 321 | 0.220 |
Why?
|
| Propensity Score | 1 | 2025 | 167 | 0.220 |
Why?
|
| Incidence | 4 | 2021 | 1383 | 0.210 |
Why?
|
| Time Factors | 5 | 2014 | 3724 | 0.210 |
Why?
|
| Reoperation | 1 | 2025 | 291 | 0.210 |
Why?
|
| Stomach | 1 | 2024 | 87 | 0.210 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2023 | 8 | 0.200 |
Why?
|
| Esophageal Diseases | 1 | 2023 | 17 | 0.200 |
Why?
|
| Morbidity | 1 | 2022 | 111 | 0.190 |
Why?
|
| Elective Surgical Procedures | 1 | 2022 | 119 | 0.180 |
Why?
|
| Bone Neoplasms | 1 | 2023 | 126 | 0.180 |
Why?
|
| Follow-Up Studies | 4 | 2014 | 2480 | 0.180 |
Why?
|
| Curriculum | 1 | 2025 | 606 | 0.170 |
Why?
|
| Treatment Outcome | 3 | 2025 | 5691 | 0.170 |
Why?
|
| Logistic Models | 1 | 2024 | 1270 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 423 | 0.150 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 142 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2022 | 340 | 0.150 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 2621 | 0.140 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2737 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 788 | 0.120 |
Why?
|
| New York City | 2 | 2012 | 91 | 0.120 |
Why?
|
| Prognosis | 3 | 2014 | 1769 | 0.110 |
Why?
|
| Thoracic Neoplasms | 1 | 2014 | 14 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 374 | 0.100 |
Why?
|
| Mediastinal Neoplasms | 1 | 2013 | 21 | 0.100 |
Why?
|
| False Positive Reactions | 1 | 2012 | 79 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2013 | 229 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 220 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2013 | 209 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 97 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2013 | 309 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2013 | 5527 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 1103 | 0.080 |
Why?
|
| Smoking | 1 | 2014 | 861 | 0.080 |
Why?
|
| Disease Progression | 1 | 2013 | 1176 | 0.070 |
Why?
|
| Length of Stay | 1 | 2012 | 818 | 0.070 |
Why?
|
| Young Adult | 2 | 2013 | 4780 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2021 | 930 | 0.060 |
Why?
|
| Radius | 1 | 2023 | 16 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 93 | 0.050 |
Why?
|
| Necrosis | 1 | 2023 | 144 | 0.050 |
Why?
|
| Hematoxylin | 1 | 2022 | 11 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2022 | 12 | 0.050 |
Why?
|
| Cause of Death | 2 | 2014 | 222 | 0.050 |
Why?
|
| Endosonography | 1 | 2022 | 27 | 0.050 |
Why?
|
| Cytodiagnosis | 1 | 2022 | 46 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 279 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 29 | 0.050 |
Why?
|
| Brazil | 1 | 2021 | 100 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2020 | 67 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 199 | 0.040 |
Why?
|
| Walking | 1 | 2020 | 240 | 0.040 |
Why?
|
| Medicare | 1 | 2021 | 611 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 964 | 0.030 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 2 | 0.030 |
Why?
|
| Mediastinoscopy | 1 | 2013 | 8 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 101 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 128 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 192 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 91 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 18 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 71 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 249 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 239 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 448 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 587 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 735 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 457 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2012 | 870 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 2604 | 0.010 |
Why?
|